HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genomma Enjoys Strong Q2 Thanks To Big Gains in US

Executive Summary

Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

You may also be interested in...



People On The Move: Appointments At UPSA, Bionorica And MHRA

The latest European consumer health people news: Sanofi Consumer Healthcare's Van Rycke named CEO of UPSA; Bionorica's global business head steps down; MHRA names its first chief safety officer.

Swisse Pens Deal To Use ChromaDex’ Niagen In Supplements

Australian-heritage supplements brand Swisse has secured the rights to use ChromaDex' patented Niagen ingredient - marketed to help consumers "age better" - in a new product range.

LATAM Q1 Sales: Mexico's Genomma And Brazil's Hypera Report Gains

Genomma Lab reports OTC sales rise in Q1 thanks to gains in its LATAM region, while Brazil's Hypera posts big jump in turnover due to acquisitions. 

Topics

Related Companies

UsernamePublicRestriction

Register

RS150331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel